Literature DB >> 21933944

Immunity and bacterial colonisation in bronchiectasis.

Deborah Whitters1, Robert Stockley.   

Abstract

BACKGROUND: Non-cystic fibrosis bronchiectasis is characterised by irreversibly dilated bronchi usually associated with chronic sputum production, bacterial colonisation of the lower respiratory tract, inflammation and frequent exacerbations. Irrespective of the underlying cause, this represents failure of the host defence to maintain sterility of the respiratory tract.
OBJECTIVE: To review the interactions and associations of non-cystic fibrosis bronchiectasis with the inate and adaptive immune systems with particular emphasis on known failure of local defences established deficiencies of the adaptive immune system. In addition we wished to explore potential subtle changes in the host defence which can lead to bacterial colonisation together with bacterial factors that aid colonisation of the lower respiratory tract and impair antibiotic response. This latter concept is considered with particular reference to Pseudomonas aeruginosa, which is often found in the airway secretions of patients with non-cystic fibrosis bronchiectasis and may act as a model for other organisms.
METHODS: An extensive literature review was undertaken to provide a comprehensive review of immunity and bacterial colonisation in non-cystic fibrosis bronchiectasis, with focus on in vitro studies examining bacterial factors which may facilitate colonisation together with potential implications for management.
CONCLUSION: These themes provide a review of the current understanding of non-cystic fibrosis bronchiectasis together with areas for future research and potential therapeutic strategies.

Entities:  

Mesh:

Year:  2011        PMID: 21933944     DOI: 10.1136/thoraxjnl-2011-200206

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  16 in total

1.  Understanding persistent bacterial lung infections: clinical implications informed by the biology of the microbiota and biofilms.

Authors:  Alexa A Pragman; John P Berger; Bryan J Williams
Journal:  Clin Pulm Med       Date:  2016-03

Review 2.  Antibody-Dependent Enhancement of Bacterial Disease: Prevalence, Mechanisms, and Treatment.

Authors:  Von Vergel L Torres; Carrie F Coggon; Timothy J Wells
Journal:  Infect Immun       Date:  2021-03-17       Impact factor: 3.441

3.  Aberrant epithelial remodeling with impairment of cilia architecture in non-cystic fibrosis bronchiectasis.

Authors:  Zhuang-Gui Chen; Ying-Ying Li; Zhao-Ni Wang; Ming Li; Hui-Fang Lim; Yu-Qi Zhou; Liang-Ming Cai; Ya-Ting Li; Li-Fen Yang; Tian-Tuo Zhang; De-Yun Wang
Journal:  J Thorac Dis       Date:  2018-03       Impact factor: 2.895

4.  Bronchiectasis.

Authors:  Changhwan Kim; Dong-Gyu Kim
Journal:  Tuberc Respir Dis (Seoul)       Date:  2012-11-30

5.  A grand challenge of factors influencing lung health.

Authors:  Laurent P Nicod
Journal:  Front Med (Lausanne)       Date:  2014-05-01

6.  Increased severity of respiratory infections associated with elevated anti-LPS IgG2 which inhibits serum bactericidal killing.

Authors:  Timothy J Wells; Deborah Whitters; Yanina R Sevastsyanovich; Jennifer N Heath; John Pravin; Margaret Goodall; Douglas F Browning; Matthew K O'Shea; Amy Cranston; Anthony De Soyza; Adam F Cunningham; Calman A MacLennan; Ian R Henderson; Robert A Stockley
Journal:  J Exp Med       Date:  2014-08-11       Impact factor: 14.307

7.  Inhaled colistin in patients with bronchiectasis and chronic Pseudomonas aeruginosa infection.

Authors:  Charles S Haworth; Juliet E Foweraker; Peter Wilkinson; Robert F Kenyon; Diana Bilton
Journal:  Am J Respir Crit Care Med       Date:  2014-04-15       Impact factor: 21.405

8.  To investigate the prevention of OM-85 on bronchiectasis exacerbations (iPROBE) in Chinese patients: study protocol for a randomized controlled trial.

Authors:  Jinming Gao; Xiang Gao; Lingfei Kong
Journal:  Trials       Date:  2014-04-29       Impact factor: 2.279

9.  Combined inhaled corticosteroid and long-acting β2-adrenergic agonist therapy for noncystic fibrosis bronchiectasis with airflow limitation: An observational study.

Authors:  Ping Wei; Jia-Wei Yang; Hai-Wen Lu; Bei Mao; Wen-Lan Yang; Jin-Fu Xu
Journal:  Medicine (Baltimore)       Date:  2016-10       Impact factor: 1.889

Review 10.  The Role of the Immune Response in the Pathogenesis of Bronchiectasis.

Authors:  Paul T King
Journal:  Biomed Res Int       Date:  2018-03-18       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.